Protocol โบ The three phases ยท Last reviewed 2026-05-16
The three treatment phases
Summary
The Dutch approach distinguishes three treatment phases: (1) puberty suppression with GnRH agonists, originally presented as fully reversible, (2) cross-sex hormones, a partially reversible phase, and (3) gender-affirming surgery, which is irreversible. The WPATH Standards of Care versions 6 and 7 divided the treatment of adolescents into the same three categories (source).
1. Overview
| Phase | Intervention | Age (original) | Reversibility |
|---|---|---|---|
| 1 | Psychological diagnostics + GnRHa | from 12, Tanner 2 | Fully reversible (as originally stated) |
| 2 | Cross-sex hormones (oestrogens / testosterone) | ~16 | Partially reversible |
| 3 | Gender-affirming surgery | โฅ 18 | Irreversible |
2. Phase 1 โ Diagnostics and puberty suppression
The first phase combines psychological assessment with suppression of endogenous puberty using GnRH agonists.1 In the Dutch approach puberty is paused at Tanner stage 2; the Swedish guideline recommends Tanner stage 3 (source).
According to the Cass Review 2024 the original rationale (Cohen-Kettenis 1998) was two-fold: to support the diagnostic procedure by buying time to think, and to improve the longer-term ability to pass in the preferred gender (source). Cass also notes that most guidelines emphasise full reversibility as a justification while highlighting possible adverse effects on bone health and uncertainty regarding cognitive development, and Biggs (2023) concludes that the claims that the intervention is reversible and a tool for diagnosis are increasingly implausible (source).2
3. Phase 2 โ Cross-sex hormone therapy
From around age 16, cross-sex hormone therapy is added: oestrogens for MtF patients, testosterone for FtM patients (source). The Endocrine Society guideline calls this a "partially irreversible treatment" (source).3
4. Phase 3 โ Surgery
In the Dutch approach, surgical interventions were considered after age 18, with exceptions in some cases (source).
Critical note
The three-way division reversible / partially reversible / irreversible is under pressure. (i) The Cass Review 2024 reports that bone density is compromised during puberty suppression and that height gain may lag behind, and that much longer follow-up is needed to see whether bone health recovers; it also raises the concern that blocking adolescent hormone surges may disrupt brain maturation, which could affect later decision-making, and says it is not known whether this is the case (source) (see also SBU 2022). (ii) According to Cass, the evidence to date suggests that blockers do not substantially reduce adult height in transgender females nor increase it in transgender males, but starting suppression too early in birth-registered males can make a later vaginoplasty more difficult (source). (iii) The vast majority of those who start puberty suppression continue to cross-sex hormones: 98% (43 of 44) in the UK early intervention study, 98% in one Dutch cohort and 93% of 707 eligible adolescents in another; Cass concludes that these data suggest blockers are not buying time to think (source) (follow-up overview).4
See also
- Original protocol description: Delemarre 2006
- Age and Tanner criteria per phase: Age criteria
- Informed consent around each phase: Informed consent
- Outcome measures per phase: Follow-up structure
- Continuation rates: Follow-up studies overview
- Systematic evaluation of the phases: Cass Review, SBU
- People register โ Cohen-Kettenis, Delemarre, de Vries.
- International comparison โ how other countries handle the phases.
- Timeline โ protocol development chronologically.
- FAQ ยท Glossary ยท For parents.
Footnotes
- Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents. Eur J Endocrinol. 2006;155(S1):S131โ7.
- Cass H. Independent review of gender identity services for children and young people: final report. NHS England; April 2024. p. 174โ186.
- Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons. J Clin Endocrinol Metab. 2017;102(11):3869โ903.
- van der Loos MATC, et al. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. Lancet Child Adolesc Health. 2022;6(12):869โ75.